# Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

> **NCT03338998** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Hemorrhagic Stroke
- Intracerebral Hemorrhage (ICH)

## Interventions

- **DRUG:** BAF312 solution
- **DRUG:** Matching Placebo for BAF312 solution
- **DRUG:** BAF312 tablet
- **DRUG:** Matching Placebo for BAF312 tablet

## Key facts

- **NCT ID:** NCT03338998
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-24
- **Primary completion:** 2020-05-13
- **Final completion:** 2020-05-13
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03338998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03338998, "Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03338998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*